The pharmaceutical company Viking has recently become one of the most volatile stocks on Wall Street due to the announcement ...

Here are the key points about Viking Therapeutics' oral obesity drug VK2735: Early-Stage Trial Results: All doses of VK2735 ...

AstraZeneca PLC shed GBP15 billion of market capitalization on Tuesday, after investors were underwhelmed by early data from a trial of a weight-loss pill. The company (UK:AZN) said its lead product ...

Losing more than 8% of weight in less than a month. This is the promise of a pill under experimentation in the laboratories ...

AstraZeneca’s new obesity pill, licensed from China’s Eccogene last year, has shown initial promise in early-stage trials.

PicoCELA Inc. has filed to raise $10M in a U.S. IPO to fund inventory and product R&D. Click here for more on PCLA stock, and why my outlook on the IPO is to sell.

Viking Therapeutics announced its oral formulation of VK2735 has scored in a Phase I trial at ObesityWeek 2024.

With the FDA approval of the first specific drug for Metabolic Associated Steatohepatitis (MASH) in March this year, Madrigal’s Rezdiffra is a pioneer in a market set for rapid change. | With the FDA ...